Shots:
- The launch of Tacrolimus capsules follows from approval of US FDA in Nov. 2020 and underscores Biocon relentless pursuit to make affordable healthcare accessible
- It has particularly effective in treating patients of renal transplant for more than 2 decades
- Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in the treatment of organ transplant patients, which reduces the body’s ability to reject a transplanted organ
Click here to read full press release/ article | Ref: Biocon | Image: Business Standard
The post Biocon Launches Tacrolimus Capsules in the US first appeared on PharmaShots.
